---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-044353"
form_type: "8-K"
ticker: null
cik: "0001797768"
company_name: "Kinnate Biopharma Inc."
filed_at: "2023-09-18T23:59:59+00:00"
generated_at: "2026-06-10T15:04:22.571852+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kinnate cuts workforce 70%, reprioritizes pipeline; cash runway into Q2 2026

## Summary
- Workforce reduction of ~70% to 28 employees; China subsidiary Kinnjiu separation.
- One-time severance cost ~$2.0M in Q3 2023; plan completion expected in Q4 2023.
- Cash $204.3M as of June 30, 2023; expected runway into at least Q2 2026.
- Exarafenib combo in NRAS mutant melanoma: 38% ORR; two doses to be selected in Q4 2023.
- KIN-8741 IND filing and CDK4 candidate nomination planned for Q4 2023; KIN-7136 paused.

## SEC filing metadata
- accession: 0001140361-23-044353
- form_type: 8-K
- cik: 0001797768
- company_name: Kinnate Biopharma Inc.
- filed_at: 2023-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01, 2.05, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1797768/000114036123044353/0001140361-23-044353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1797768/000114036123044353/ef20010841_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-044353
- JSON: https://secwatch.observer/filing/0001140361-23-044353.json
- Plain text: https://secwatch.observer/filing/0001140361-23-044353.txt

## Key facts
- Earnings Releases
  Kinnate Biopharma Inc. updated its as of June 30, 2023 guidance (initiated).
  - Period: as of June 30, 2023
  - Guidance: initiated
  - Result: guidance update
  source text: Cash, cash equivalents and investments of $204.3 million as of June 30, 2023, anticipated to fund operations into at least the second quarter of 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1797768/000114036123044353/0001140361-23-044353-index.htm
- Restructurings & Charges
  Kinnate Biopharma Inc. announced a restructuring with charges of approximately $2.0 million (approximately 70%).
  - Type: restructuring
  - Charge: approximately $2.0 million
  - Headcount: approximately 70%
  source text: Kinnjiu Biopharma. The Company initiated the Plan effective September 18, 2023. In connection with this Plan, the Company expects to incur one-time costs of approximately $2.0 million, primarily in the third quarter of 2023, relating to severance and related benefits. Cash payments related to these expenses will be paid out, and the Plan is expected to be
  evidence_url: https://www.sec.gov/Archives/edgar/data/1797768/000114036123044353/0001140361-23-044353-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.